CT引导经皮冷冻消融治疗高危部位肝细胞癌的疗效与安全性
回顾性分析2018年1月至2021年12月天津医科大学肿瘤医院685例接受经皮冷冻消融的肝细胞癌患者,其中106例病灶位于高危部位(距心脏/大血管、膈肌、胃肠道、胆囊最小距离小于10毫米)。高危组与非高危组术中技术成功率均为100%,12和24个月完全消融率组间无显著差异(P>0.05),多因素分析显示肿瘤边缘距高危部位≤5毫米及术前TACE是消融效果的独立危险因素。结论认为CT引导经皮冷冻消融对高危部位肝细胞癌安全有效,可作为手术治疗的替代选择。
要点
- 高危部位定义为病灶距心脏/大血管、膈肌、胃肠道、胆囊最小距离小于10毫米。
- 高危组与非高危组术中技术成功率均为100%,未见与冷冻消融相关的主要并发症。
- 肿瘤边缘距高危部位≤5毫米及术前TACE是冷冻消融效果的独立危险因素。
核心结论
- CT引导经皮冷冻消融对高危部位肝细胞癌安全有效,可作为手术治疗的替代选择。
研究设计与样本
- 回顾性收集2018年1月至2021年12月天津医科大学肿瘤医院685例接受经皮冷冻消融的肝细胞癌患者资料,其中高危部位组106例、非高危部位组218例,经倾向性评分匹配后纳入95对匹配病例。
诊断标准与关键数值
- 高危部位定义为术前CT或MRI显示病灶距心脏/大血管、膈肌、胃肠道、胆囊最小距离小于10毫米;高危组12和24个月完全消融率分别为82.1%和71.7%,非高危组分别为83.9%和73.9%,匹配前后组间差异均无统计学意义(P>0.05)。
临床应用与阅片要点
- 原文结论认为CT引导经皮冷冻消融对高危部位肝细胞癌安全有效,可作为手术治疗的替代选择;多因素分析显示肿瘤边缘距高危部位≤5毫米及术前TACE是消融效果的独立危险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to assess the efficacy and safety of CT-guided percutaneous cryoablation in treating hepatocellular carcinoma (HCC) located explicitly in high-risk sites.
MATERIALS AND METHODS: Data were collected retrospectively from 685 HCC patients undergoing percutaneous cryoablation at Tianjin Medical University Cancer Hospital between January 2018 and December 2021. Of these, 106 patients had lesions in high-risk sites, defined as a minimum distance of less than 10 mm from the heart/great vessels, diaphragm, gastrointestinal tract, and gallbladder, as determined by preoperative CT or MRI imaging. Technical success rate, complete ablation rate, and complications at 1, 12, and 24 months post-surgery were evaluated. A statistical analysis of the ablation effect difference between the high-risk site and non-high-risk site groups was conducted, utilizing propensity score matching (PSM) to mitigate patient selection bias. Univariate and multivariate logistic regression analyzes were performed to identify risk factors for the incidence of coronary heart disease.
RESULTS: The study comprised 106 cases in the high-risk group and 218 cases in the non-high-risk group. After PSM analysis until December 2021, 95 matched pairs were included. Both groups demonstrated a 100% intraoperative technical success rate, and no major complications related to cryoablation were observed. Follow-up ranged from 24 to 38 months. The complete ablation rate was 82.1% and 71.7% in the high-risk group and 83.9% and 73.9% in the non-high-risk group at 12 and 24 months, respectively. There was no significant difference in complete ablation rates between the two groups before and after PSM (P > 0.05). Multivariate analysis identified the distance between the tumor edge and high-risk site ≤ 5 mm and preoperative transarterial chemoembolization (TACE) treatment as independent risk factors for cryoablation effect.
CONCLUSION: CT-guided percutaneous cryoablation proves to be a safe and effective approach for HCC patients with high-risk sites, serving as an alternative to surgical treatment.
引用
- Zhang W, Wang Y, Zhao X, et al. Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites. Acad Radiol. 2024. PMID: 38749870. doi:10.1016/j.acra.2024.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。